A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification

Vascular Pharmacology

Volumn 86, Issue , 2016, Pages 87-93

  Zhu, Dongxing ^a   Rashdan, Nabil A ^a   Chapman, Karen E ^b   Hadoke, Patrick WF ^b   MacRae, Vicky E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 4',6 DIAMIDINO 2 PHENYLINDOLE; BONE MORPHOGENETIC PROTEIN 2; CARBENOXOLONE; CORTICOSTERONE; DEHYDROCORTICOSTERONE; DEXAMETHASONE; EPLERENONE; GLUCOCORTICOID; LIPOCORTIN 5; MESSENGER RNA; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; PHOSPHATE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR PIT 1; GLUCOCORTICOID RECEPTOR; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLOOD VESSEL CALCIFICATION; CELL TRANSDIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RECEPTOR BINDING; STAINING; VASCULAR SMOOTH MUSCLE CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; APOPTOSIS; CORTICOSTERONE; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GLUCOCORTICOIDS; MICE; MICE, INBRED C57BL; MIFEPRISTONE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHATES; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SPIRONOLACTONE; VASCULAR CALCIFICATION;

EID: 84969584628     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.04.005     Document Type: Article

References (53)

1. [1] Bellows, C.G., Heersche, J.N., Aubin, J.E., Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone. Dev Biol 140:1 (1990), 132–138.
2. [2] Block, G.A., Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 54:4 (2000), 318–324.
3. −/− mice are present before and after the onset of ectopic tissue mineralization. J Investig Dermatol 134:7 (2014), 1855–1861.
4. [4] Chapman, K.E., Coutinho, A.E., Zhang, Z., Kipari, T., Savill, J.S., Seckl, J.R., Changing glucocorticoid action: 11β-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation. J Steroid Biochem Mol Biol 137 (Sep 2013), 82–92, 10.1016/j.jsbmb.2013.02.002.
5. [5] Cheng, S.L., Yang, J.W., Rifas, L., Zhang, S.F., Avioli, L.V., Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology 134:1 (1994), 277–286.
6. [6] Chmielewski, V., Drupt, F., Morfin, R., Dexamethasone-induced apoptosis of mouse thymocytes: prevention by native 7alpha-hydroxysteroids. Immunol Cell Biol 78:3 (2000), 238–246.
7. [7] Chrysis, D., Zaman, F., Chagin, A.S., Takigawa, M., Sävendahl, L., Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3′-kinase signaling pathway. Endocrinology 146:3 (2005), 1391–1397.
8. [8] Diaz de Barboza, G., Guizzardi, S., Tolosa de Talamoni, N., Molecular aspects of intestinal calcium absorption. World J Gastroenterol 21:23 (2015), 7142–7154, 10.3748/wjg.v21.i23.7142.
9. [9] Guicciardi, M.E., Mott, J.L., Bronk, S.F., Kurita, S., Fingas, C.D., Gores, G.J., Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Exp Cell Res 317:1 (2011), 107–116, 10.1016/j.yexcr.2010.10.005.
10. [10] Hadoke, P.W., Macdonald, L., Logie, J.J., Small, G.R., Dover, A.R., Walker, B.R., Intra-vascular glucocorticoid metabolism as a modulator of vascular structure and function. Cell Mol Life Sci 63:5 (2006), 565–578.
11. [11] Hadoke, P.W., Kipari, T., Seckl, J.R., Chapman, K.E., Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation. Curr Atheroscler Rep, 15(5), 2013, 320, 10.1007/s11883-013-0320-1.
12. [12] Harris, H.J., Kotelevtsev, Y., Mullins, J.J., Seckl, J.R., Holmes, M.C., Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic–pituitary–adrenal axis: analysis of 11beta-HSD-1-deficient mice. Endocrinology 142:1 (2001), 114–120.
13. [13] Hartmann, K., Koenen, M., Schauer, S., Wittig-Blaich, S., Ahmad, M., Baschant, U. et al., Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol Rev 96:2 (2016), 409–447, 10.1152/physrev.00011.2015.
14. [14] Hirata, K., Helal, F., Hadgraft, J., Lane, M.E., Formulation of carbenoxolone for delivery to the skin. Int J Pharm 20:448(2) (2013), 360–365, 10.1016/j.ijpharm.2013.03.045.
15. [15] Jaffe, I.Z., Tintut, Y., Newfell, B.G., Demer, L.L., Mendelsohn, M.E., Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 27:4 (2007), 799–805.
16. −/− mice. Arterioscler Thromb Vasc Biol 25:4 (2005), 686–691.
17. [17] Johnson, K.A., Polewski, M., Terkeltaub, R.A., Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res 102:5 (Mar 14 2008), 529–537, 10.1161/CIRCRESAHA.107.154260.
18. [18] Kirton, J.P., Wilkinson, F.L., Canfield, A.E., Alexander, M.Y., Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res 98:10 (2006), 1264–1272.
19. [19] Kaur, K., Hardy, R., Ahasan, M.M., Eijken, M., van Leeuwen, J.P., Filer, A. et al., Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis 69:6 (2010), 1185–1190.
20. [20] Li, Z.Y., Jiang, Y.M., Liu, Y.M., Guo, Z., Shen, S.N., Liu, X.M. et al., Saikosaponin D acts against corticosterone-induced apoptosis via regulation of mitochondrial GR translocation and a GR-dependent pathway. Prog Neuro-Psychopharmacol Biol Psychiatry 53 (2014), 80–89, 10.1016/j.pnpbp.2014.02.010.
21. [21] Liu, B., Zhang, H., Xu, C., Yang, G., Tao, J., Huang, J. et al., Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary cultured rat hippocampal neurons. Brain Res 1375 (2011), 59–67, 10.1016/j.brainres.2010.12.053.
22. [22] Longenecker, J.P., Kilty, L.A., Johnson, L.K., Glucocorticoid inhibition of vascular smooth muscle cell proliferation: influence of homologous extracellular matrix and serum mitogens. J Cell Biol 98:2 (1984), 534–540.
23. [23] Mackenzie, N.C., MacRae, V.E., The role of cellular senescence during vascular calcification: a key paradigm in aging research. Curr Aging Sci 4:2 (2011), 128–136.
24. [24] Mackenzie, N.C., Zhu, D., Longley, L., Patterson, C.S., Kommareddy, S., MacRae, V.E., MOVAS-1 cell line: a new in vitro model of vascular calcification. Int J Mol Med 27:5 (2011), 663–668, 10.3892/ijmm.2011.631.
25. [25] Mackenzie, N.C., Zhu, D., Milne, E.M., van't Hof, R., Martin, A., Darryl Quarles, L. et al., Altered bone development and an increase in FGF-23 expression in Enpp1(−/−) mice. PLoS One, 7(2), 2012, e32177, 10.1371/journal.pone.0032177.
26. [26] Mackenzie, N.C., Staines, K.A., Zhu, D., Genever, P., Macrae, V.E., MiRNA-221 and miRNA-222 synergistically function to promote vascular calcification. Cell Biochem Funct 32:2 (Mar 2014), 209–216, 10.1002/cbf.3005.
27. [27] Molnar, G.A., Lindschau, C., Dubrovska, G., Mertens, P.R., Kirsch, T., Quinkler, M. et al., Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 51:5 (May 2008), 1372–1378, 10.1161/HYPERTENSIONAHA.107.105718.
28. [28] Montes de Oca, A., Guerrero, F., Martinez-Moreno, J.M., Madueño, J.A., Herencia, C., Peralta, A. et al., Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One, 9(2), 2014, e89525, 10.1371/journal.pone.0089525.
29. [29] Mori, K., Shioi, A., Jono, S., Nishizawa, Y., Morii, H., Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19:9 (1999), 2112–2118.
30. [30] Murshed, M., Harmey, D., Millán, J.L., McKee, M.D., Karsenty, G., Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19:9 (2005), 1093–1104.
31. [31] Nakagawa, Y., Ikeda, K., Akakabe, Y., Koide, M., Uraoka, M., Yutaka, K.T. et al., Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo. Arterioscler Thromb Vasc Biol 30:10 (2010), 1908–1915, 10.1161/ATVBAHA.110.206185.
32. [32] Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A. et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:10 (1999), 709–717.
33. [33] Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R.A., Roniker, B. et al., Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:15 (2003), 1831–1838.
34. [34] Preusch, M.R., Rattazzi, M., Albrecht, C., Merle, U., Tuckermann, J., Schütz, G. et al., Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. Arterioscler Thromb Vasc Biol 28:12 (2008), 2158–2164, 10.1161/ATVBAHA.108.174128.
35. [35] Proudfoot, D., Skepper, J.N., Hegyi, L., Bennett, M.R., Shanahan, C.M., Weissberg, P.L., Apoptosis regulates human vascular calcification by apoptotic bodies. Circ Res 87 (2000), 1055–1062.
36. [36] Reynolds, J.L., Skepper, J.N., McNair, R., Kasama, T., Gupta, K., Weissberg, P.L. et al., Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16:10 (2005), 2920–2930.
37. [37] Richardson, R.V., Batchen, E.J., Denvir, M.A., Gray, G.A., Chapman, K.E., Cardiac GR and MR: from development to pathology. Trends Endocrinol Metab, 2015, 10.1016/j.tem.2015.10.001 (pii: S1043-2760(15)00201-5).
38. [38] Shen, C.N., Slack, J.M., Tosh, D., Molecular basis of transdifferentiation of pancreas to liver. Nat Cell Biol 2:12 (2000), 879–887.
39. [39] Shui, C., Scutt, A.M., Mouse embryo-derived NIH3T3 fibroblasts adopt an osteoblast-like phenotype when treated with 1alpha,25-dihydroxyvitamin D(3) and dexamethasone in vitro. J Cell Physiol 193:2 (2002), 164–172.
40. [40] Skrtic, D., Eanes, E.D., Membrane mediated precipitation of calcium phosphate in model liposomes with matrix vesicle-like lipid composition. Bone Miner 16 (1992), 109–119.
41. [41] Son, B.K., Akishita, M., Iijima, K., Eto, M., Ouchi, Y., Mechanism of pi-induced vascular calcification. J Atheroscler Thromb 15:2 (2008), 63–68.
42. [42] Staines, K.A., Zhu, D., Farquharson, C., MacRae, V.E., Identification of novel regulators of osteoblast matrix mineralization by time series transcriptional profiling. J Bone Miner Metab 32:3 (2014), 240–251, 10.1007/s00774-013-0493-2.
43. [43] Sun, K., Myatt, L., Enhancement of glucocorticoid-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts., 144(12), 2003 (5568-77).
44. [44] Versaci, F., Gaspardone, A., Tomai, F., Ribichini, F., Russo, P., Proietti, I. et al., Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation study. J Am Coll Cardiol 40:11 (2002), 1935–1942.
45. [45] Vizzardi, E., Nodari, S., Caretta, G., D'Aloia, A., Pezzali, N., Faden, G. et al., Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci 347:4 (2014), 271–276, 10.1097/MAJ.0b013e31829dd6b1.
46. [46] Voelkl, J., Alesutan, I., Leibrock, C.B., Quintanilla-Martinez, L., Kuhn, V., Feger, M. et al., Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 123:2 (2013), 812–822, 10.1172/JCI64093.
47. [47] Walsh, S., Jordan, G.R., Jefferiss, C., Stewart, K., Beresford, J.N., High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis. Rheumatology (Oxford) 40:1 (2001), 74–83.
48. [48] Wada, H., Glucocorticoids: mediators of vertebrate ontogenetic transitions. Gen Comp Endocrinol 156:3 (2008), 441–453, 10.1016/j.ygcen.2008.02.004.
49. [49] Zhu, D., Mackenzie, N.C., Millán, J.L., Farquharson, C., MacRae, V.E., The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One, 6(5), 2011, e19595, 10.1371/journal.pone.0019595.
50. [50] Zhu, D., Mackenzie, N.C., Farquharson, C., Macrae, V.E., Mechanisms and clinical consequences of vascular calcification. Front Endocrinol (Lausanne), 6(3:95), 2012, 10.3389/fendo.
51. [51] Zhu, D., Mackenzie, N.C., Millan, J.L., Farquharson, C., MacRae, V.E., A protective role for FGF-23 in local defence against disrupted arterial wall integrity?. Mol Cell Endocrinol 372:1–2 (2013), 1–11, 10.1016/j.mce.2013.03.008.
52. [52] Zhu, D., Mackenzie, N.C., Millan, J.L., Farquharson, C., Macrae, V.E., Upregulation of IGF2 expression during vascular calcification. J Mol Endocrinol 52:2 (2014), 77–85, 10.1530/JME-13-0136.
53. [53] Zhu, D., Mackenzie, N.C., Shanahan, C.M., Shroff, R.C., Farquharson, C., MacRae, V.E., BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1 mediated pathway. J Cell Mol Med 19:1 (2015), 165–174, 10.1111/jcmm.12373.